Subramonian, D., Phanhthilath, N., Rinehardt, H., Flynn, S., Huo, Y., Zhang, J., . . . Zage, P. E. (2020). Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways. Br J Cancer.
Stile di citazione ChicagoSubramonian, Divya, et al. "Regorafenib Is Effective against Neuroblastoma in Vitro and in Vivo and Inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun Pathways." Br J Cancer 2020.
Citazione MLASubramonian, Divya, et al. "Regorafenib Is Effective against Neuroblastoma in Vitro and in Vivo and Inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun Pathways." Br J Cancer 2020.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.